Irvine Scientific Adds R&D Center in CA
PTSM: Pharmaceutical Technology Sourcing and Management
The company added a 40,000-ft2 purpose-built R&D center at 17112 Armstrong Ave, Irvine, CA.
On June 13, 2017, Irvine Scientific announced the expansion of its Orange County, CA offices and laboratories, with the addition of a 40,000-ft2 purpose-built R&D center at 17112 Armstrong Ave, Irvine, CA. According to the company, this follows the significant expansion of its R&D facilities less than five years ago.
The new building will also contain other departments that currently reside within its southern CA headquarters enabling the company to expand other capabilities, such as media customization for customers, conducted at its headquarters in Santa Ana. Along with the other facilities in Santa Ana, CA, this increases the total space occupied by Irvine Scientific in Orange County to more than 140,000 ft2.
With the opening of the new facility, Irvine Scientific plans to expand the laboratories and staff located in its main headquarters. As the company continues to grow, it intends to continue to expand its offering of products and services to biopharmaceutical, stem and immune cell therapy companies, and medical devices for the IVF laboratories worldwide.
Source: Irvine Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
